Alan H Bryce

763 posts

Alan H Bryce banner
Alan H Bryce

Alan H Bryce

@AlanBryce9

Medical oncologist and cancer researcher specializing in Prostate Cancer. Chief Clinical Officer, City of Hope Arizona, Professor of Molecular Medicine,Tgen

Phoenix, AZ شامل ہوئے Temmuz 2019
622 فالونگ1.3K فالوورز
Thor Halfdanarson
Thor Halfdanarson@OncoThor·
Rage, rage against the dying of the light… False spring #6 this year in Rochester. How was your commute home from work…?
Thor Halfdanarson tweet mediaThor Halfdanarson tweet media
English
2
0
9
430
Alan H Bryce
Alan H Bryce@AlanBryce9·
Alan H Bryce tweet media
English
1
0
1
61
Tyler Seibert - tmp account. Go follow @TylerSbrt
Oncology friends 🌍🌏🌎 🙏🏼 share 📸 while out 🏃🏼🏃🏽‍♀️🚶🏿‍♂️🚴🏾‍♀️⛷️🏂🏄🏽‍♀️ 🌊🏝️☀️🏔️🌳🌻🌧️❄️ 🏃🏼by💧 @aadel_chaudhuri @scserendipity1 @_ShankarSiva @SimonMDLord @ethansgrumps @cwspeers @shiv_smith @lauren_henke @ResearchWyatt @mleapman @PaulSargos @SimonLo21054188 @NiuSanford @alison_tree
Tyler Seibert - tmp account. Go follow @TylerSbrt tweet media
Tyler Seibert - tmp account. Go follow @TylerSbrt@TylerSbrt7

🥇First post with new account has to be:🏃🏼 by 💧 #EAU26 (#ProstateCancer #radonc content coming soon)

English
5
3
16
4.1K
Alan H Bryce
Alan H Bryce@AlanBryce9·
Scotland v Japan match today. Thank goodness it’s a friendly!!
Alan H Bryce tweet media
English
1
1
4
360
Alan H Bryce
Alan H Bryce@AlanBryce9·
@scserendipity1 We support both squads so this is difficult! My Zlatan Bryceahimovic had 1 goal and 1 assist in a 3-3 draw today. His man bun was flying around the field.
English
1
0
1
46
Simon C
Simon C@scserendipity1·
@AlanBryce9 I’m presuming we are supporting Scotland! Declan ‘Zlatan’ Bryce got his kilt on?
English
1
0
0
90
Alan H Bryce
Alan H Bryce@AlanBryce9·
25% discordance between PSA and radiographic progression is also what we saw in PREVAIL and CHAARTED so the finding is clearly consistent. If it feels high that is likely because your real world definition for PSA progression is more liberal. nature.com/articles/pcan2… sciencedirect.com/science/articl…
Simon C@scserendipity1

I did struggle with this despite being kindly involved in some of the studies. 25% feels high but anecdote versus data never a good thing. @Prof_IanD @ChrisSweens1 guide me. No PSA progression but LDH, LFTs, FBC, Albumin. Would they miss this? It’s clearly more than I feel clinically which would be closer to 10% @Silke_Gillessen @alison_tree @AdamSharpMedOnc @AlanBryce9

English
0
0
3
381
Alan H Bryce ری ٹویٹ کیا
UroToday.com
UroToday.com@urotoday·
Consensus recommendations for PSMA PET imaging in metastatic #ProstateCancer. @TDorffOnc @cityofhope joins @AlanBryce9 breaking down key takeaways from the US Prostate Cancer Consensus Conference—tackling real-world gray areas in imaging and treatment. Highlights include when to use PSMA PET vs conventional imaging, guidance on prostate radiation in low-volume mCSPC, and when metastasis-directed therapy fits for oligometastatic #mCRPC. #WatchNow on UroToday > bit.ly/4jPAX07
UroToday.com tweet media
English
0
3
4
623
Alan H Bryce
Alan H Bryce@AlanBryce9·
Spring Training is one of the great things about living in Arizona. My family looks forward to it every year. Go Guardians!
English
0
0
5
130
Alan H Bryce
Alan H Bryce@AlanBryce9·
Thank you to @CleGuardians. Today is the first day of Spring Training and they are raising money to support cancer care at @cityofhope.
Alan H Bryce tweet media
English
1
4
11
839
Alan H Bryce
Alan H Bryce@AlanBryce9·
@allisonoconn @ReneeSaliby It’s recommended for all metastatic, not just de novo. While that is clearly implied by the second category, I think the inclusion of the term de novo may create confusion here.
English
0
0
1
20
Allison Fitzgerald, MD, PhD
Allison Fitzgerald, MD, PhD@allisonoconn·
Today I learned germline genetic testing is recommended for prostate cancer patients if they’re: 1. De novo metastatic 2. High risk or very high risk 3. Intermediate risk with either a family history or intraductal carcinoma on pathology.
English
3
9
43
3.1K
Nico Gagelmann
Nico Gagelmann@NicoGagelmann·
What's your favorite?
Nico Gagelmann tweet media
English
40
7
49
16.5K
Alan H Bryce
Alan H Bryce@AlanBryce9·
Same. This is an article I have shared with countless residents and fellows over the years. Also, the poem Otherwise that he references is part of our family tradition where I have my boys read poetry to their mother.
Ramy Sedhom, MD, FASCO@ramsedhom

A favorite read, I find myself revisiting time and time again @DavidSteensma - the loss of our patients is a hard part of oncology & it is important to take pride in caring so well for those who die ascopubs.org/doi/full/10.12…

English
0
0
6
773
Alan H Bryce ری ٹویٹ کیا
Advanced Prostate Cancer Consensus Conference
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis sciencedirect.com/science/articl… This living network meta-analysis of 11 phase 3 trials shows that treatment benefits in metastatic hormone-sensitive #ProstateCancer differ by disease volume and timing. Triplet therapy (ARPI + docetaxel + ADT) offers the greatest survival advantage only in patients with synchronous high-volume disease. For all other subgroups—synchronous low-volume, metachronous high-volume, and metachronous low-volume—ARPI + ADT alone is the preferred option and outperforms ADT alone or docetaxel + ADT, with no clear added benefit from adding docetaxel when ARPIs are available. Irbaz Bin Riaz @PrafulRavi1 @Parminder1699 @neerajaiims @amerseburger @AarmstrongDuke @BertrandTOMBAL Karim Fizazi @AlanBryce9 @OncoAlert 🚨 @Silke_Gillessen @AOmlin @nataliagandur
Advanced Prostate Cancer Consensus Conference tweet media
English
6
28
64
22.2K
Alan H Bryce ری ٹویٹ کیا
Neeraj Agarwal, MD, FASCO
Neeraj Agarwal, MD, FASCO@neerajaiims·
Just in @EUplatinum 👉Big congrats to @IrbazRiaz & team for this superb meta-analysis! 👏 Their living meta analysis framework shows how digital tools e.g. AI/LLMs set a new standard for timely synthesis k sharing of the evidence. @AlanBryce9 @OncoAlert @urotoday @PCF_Science
Neeraj Agarwal, MD, FASCO tweet mediaNeeraj Agarwal, MD, FASCO tweet media
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano

Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis sciencedirect.com/science/articl… This living network meta-analysis of 11 phase 3 trials shows that treatment benefits in metastatic hormone-sensitive #ProstateCancer differ by disease volume and timing. Triplet therapy (ARPI + docetaxel + ADT) offers the greatest survival advantage only in patients with synchronous high-volume disease. For all other subgroups—synchronous low-volume, metachronous high-volume, and metachronous low-volume—ARPI + ADT alone is the preferred option and outperforms ADT alone or docetaxel + ADT, with no clear added benefit from adding docetaxel when ARPIs are available. Irbaz Bin Riaz @PrafulRavi1 @Parminder1699 @neerajaiims @amerseburger @AarmstrongDuke @BertrandTOMBAL Karim Fizazi @AlanBryce9 @OncoAlert 🚨 @Silke_Gillessen @AOmlin @nataliagandur

English
2
21
35
7.5K